Nephronophthisis (NPHP), the most common monogenic cause of end‐stage renal disease (ESRD) during the first three decades of life, is responsible for 2.4%--15% of ESRD in this population. The estimated incidence varies from 1:50 000 live births in Finland to 1:1 000 000 in the United States.[1](#nep13393-bib-0001){ref-type="ref"} It is caused by mutations in many genes that encode nephrocystin protein, which is involved in the function of primary cilia, basal bodies, and centrosomes. These mutations result in renal disease and extra‐renal manifestations.[2](#nep13393-bib-0002){ref-type="ref"} This review provides an update about the recent advances in the field of NPHP.

CLINICAL MANIFESTATIONS OF NPHP {#nep13393-sec-0002}
===============================

Nephronophthisis is characterized by reduced ability of the kidneys to concentrate solutes, chronic tubulointerstitial nephritis, cystic renal disease, and progression to ESRD before age 30. The typical clinical symptoms of NPHP include polyuria, polydipsia with regular fluid intake at night, secondary enuresis, anaemia, and growth retardation. Patients with NPHP typically have a "bland" urinalysis without evidence of proteinuria, hematuria, or cellular elements until the late stage, when proteinuria may develop into secondary glomerulosclerosis.

Clinically, three clinical subtypes of NPHP have been recognized based on the median age of onset of ESRD: infantile, juvenile, and adolescent/adult.[3](#nep13393-bib-0003){ref-type="ref"} The main characteristics of these three subtypes of NPHP are summarized in Table [1](#nep13393-tbl-0001){ref-type="table"}. However, there have been several case reports of patients with NPHP who progressed to ESRD between the ages of 27 and 56 years.[4](#nep13393-bib-0004){ref-type="ref"}, [5](#nep13393-bib-0005){ref-type="ref"}, [6](#nep13393-bib-0006){ref-type="ref"} These cases of NPHP extend the age of ESRD from birth to the sixth decade of life.

###### 

Main features of three clinical subtypes of nephronophthisis (NPHP)

  Item                              Infantile NPHP                                                                                                                                                               Juvenile NPHP                                                                                                                                                                                                                               Adolescent/adult NPHP
  --------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------
  Onset of ESRD (median in years)   1 year                                                                                                                                                                       13 years                                                                                                                                                                                                                                    19 years
  Clinical manifestations           Oligohydramnios sequence in utero (limb contractures, pulmonary hypoplasia, and facial dysmorphisms), severe renal failure in the first years of life, severe hypertension   Impaired urinary concentrating ability (polyuria and polydipsia), impaired sodium reabsorption (hypovolaemia, hyponatraemia, chronic kidney disease (severe anaemia, growth retardation), proteinuria (late stage), normal blood pressure   Similar to juvenile NPHP
  Renal ultrasound                  Enlarged kidneys, large cortical microcysts, absent medullary cysts                                                                                                          Normal‐sized or smaller hyperechogenic kidneys with corticomedullary cysts and poor corticomedullary differentiation                                                                                                                        Similar to juvenile NPHP
  Renal histology                   Tubular atrophy, usually lack tubular basement membrane change, interstitial fibrosis, collecting tubule cystic dilatation, enlarged kidneys                                 Tubular atrophy, tubular basement membrane disruption, cysts at the corticomedullary border, diffuse interstitial fibrosis with chronic inflammation                                                                                        Similar to juvenile NPHP
  Extra‐renal association           Liver fibrosis, severe cardiac valve or septal defects, recurrent bronchial infections                                                                                       Retinal degeneration, cerebellar vermis aplasia, gaze palsy, liver fibrosis, skeletal defects                                                                                                                                               Similar to juvenile NPHP
  Typical gene                      *NPHP2/INVS, NPHP3, NPHP12/TTC21B/JBTS11, NPHP14 /ZNF423, NPHP18 /CEP83*                                                                                                     All NPHP genes except *NPHP2/INVS*                                                                                                                                                                                                          *NPHP3, NPHP4, NPHP9/NEK8*

Extra‐renal manifestations occur in approximately 10%--20% of patients, including retinitis pigmentosa,[7](#nep13393-bib-0007){ref-type="ref"} skeletal defects,[8](#nep13393-bib-0008){ref-type="ref"} hepatic fibrosis,[9](#nep13393-bib-0009){ref-type="ref"} neurologic abnormalities,[10](#nep13393-bib-0010){ref-type="ref"} and cardiac defects.[11](#nep13393-bib-0011){ref-type="ref"} NPHP is also a major clinical finding in several syndromes, including Senior‐Loken, Joubert, Meckel‐Gruber, Cogan, and Sensenbrenner syndromes, and asphyxiating thoracic dystrophy (ATD, also known as Jeune syndrome). A summary of the main extra‐renal manifestations associated with NPHP is described in Table [2](#nep13393-tbl-0002){ref-type="table"}.

###### 

Extra‐renal manifestations associated with nephronophthisis (NPHP)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Involved organ           Manifestations                                                                                                                                      Associated syndrome
  ------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Eye                      Retinitis pigmentosa\                                                                                                                               Senior‐Løken syndrome (retinitis pigmentosa)\
                           Alstrom                                                                                                                                             Arima syndrome (cerebro‐oculo‐hepato‐renal syndrome)\
                                                                                                                                                                               Alstrom syndrome (early cone‐rod retinal dystrophy and blindness, hearing loss, childhood obesity, type 2 diabetes mellitus, cardiomyopathy, fibrosis, and multiple organ failure)\
                                                                                                                                                                               RHYNS (retinitis pigmentosa, hypopituitarism, skeletal dysplasia)\
                                                                                                                                                                               Joubert syndrome (cerebellar vermis hypoplasia)

  Oculomotor apraxia       Cogan syndrome (congenital oculomotor apraxia (absence or impairment of controlled, voluntary, and retinitis pigmentosa horizontal eye movement)\   
                           Joubert syndrome                                                                                                                                    

  Nystagmus                Joubert syndrome                                                                                                                                    

  Coloboma                 Joubert syndrome\                                                                                                                                   
                           COACH (cerebellar vermis hypo/aplasia, oligophrenia, ataxia, ocular coloboma and hepatic fibrosis)                                                  

  Central nervous system   Encephalocele                                                                                                                                       Meckel‐Gruber syndrome (central nervous system malformation, bilateral renal cystic dysplasia, cleft palate, polydactyly, ductal proliferation in the portal area of the liver, pulmonary hypoplasia, and situs inversus)

                           Vermis aplasia                                                                                                                                      Joubert syndrome\
                                                                                                                                                                               COACH

                           Hypopituitarism                                                                                                                                     RHYNS

  Liver                    Liver fibrosis                                                                                                                                      Boichis syndrome (progressive kidney dysfunction, liver fibrosis, excessive urination, excessive thirst, failure to thrive, retarded growth, progressive kidney insufficiency, anaemia, metabolic acidosis, weakness)\
                                                                                                                                                                               Meckel‐Gruber syndrome\
                                                                                                                                                                               Arima syndrome\
                                                                                                                                                                               Joubert syndrome\
                                                                                                                                                                               COACH

  Bone                     Cone‐shaped epiphysis                                                                                                                               Mainzer‐Saldino syndrome (phalangeal cone‐shaped epiphyses, chronic renal failure, and early‐onset, severe retinal dystrophy)

                           Polydactyly                                                                                                                                         Joubert syndrome\
                                                                                                                                                                               Meckel‐Gruber syndrome\
                                                                                                                                                                               Bardet‐Biedl syndrome (retinitis pigmentosa, obesity, deafness)\
                                                                                                                                                                               Ellis van Creveld syndrome (short limbs, short ribs, postaxial polydactyly, dysplastic nails and teeth)\
                                                                                                                                                                               Jeune syndrome (asphyxiating thoracic dystrophy)\
                                                                                                                                                                               Sensenbrenner syndrome (craniosynostosis, short limbs, brachydactyly, narrow thorax, and facial anomalies)

                           Skeletal abnormalities                                                                                                                              Sensenbrenner syndrome\
                                                                                                                                                                               Ellis van Creveld syndrome

  Heart                    Cardiac malformation                                                                                                                                

                           Situs inversus                                                                                                                                      Meckel‐Gruber syndrome

  Lung                     Bronchiectasis                                                                                                                                      

  Other                    Ulcerative colitis                                                                                                                                  
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GENOTYPE--PHENOTYPE CORRELATION OF NPHP {#nep13393-sec-0003}
=======================================

To date, more than 25 different genes have been found to be associated with NPHP (Table [3](#nep13393-tbl-0003){ref-type="table"}).[2](#nep13393-bib-0002){ref-type="ref"}, [12](#nep13393-bib-0012){ref-type="ref"}, [13](#nep13393-bib-0013){ref-type="ref"}, [14](#nep13393-bib-0014){ref-type="ref"}, [15](#nep13393-bib-0015){ref-type="ref"}, [16](#nep13393-bib-0016){ref-type="ref"}, [17](#nep13393-bib-0017){ref-type="ref"}, [18](#nep13393-bib-0018){ref-type="ref"}, [19](#nep13393-bib-0019){ref-type="ref"}, [20](#nep13393-bib-0020){ref-type="ref"}, [21](#nep13393-bib-0021){ref-type="ref"}, [22](#nep13393-bib-0022){ref-type="ref"}, [23](#nep13393-bib-0023){ref-type="ref"}, [24](#nep13393-bib-0024){ref-type="ref"}, [25](#nep13393-bib-0025){ref-type="ref"}, [26](#nep13393-bib-0026){ref-type="ref"}, [27](#nep13393-bib-0027){ref-type="ref"}, [28](#nep13393-bib-0028){ref-type="ref"}, [29](#nep13393-bib-0029){ref-type="ref"}, [30](#nep13393-bib-0030){ref-type="ref"}, [31](#nep13393-bib-0031){ref-type="ref"}, [32](#nep13393-bib-0032){ref-type="ref"}, [33](#nep13393-bib-0033){ref-type="ref"}, [34](#nep13393-bib-0034){ref-type="ref"}, [35](#nep13393-bib-0035){ref-type="ref"}, [36](#nep13393-bib-0036){ref-type="ref"}, [37](#nep13393-bib-0037){ref-type="ref"}, [38](#nep13393-bib-0038){ref-type="ref"}, [39](#nep13393-bib-0039){ref-type="ref"}, [40](#nep13393-bib-0040){ref-type="ref"}, [41](#nep13393-bib-0041){ref-type="ref"}, [42](#nep13393-bib-0042){ref-type="ref"}, [43](#nep13393-bib-0043){ref-type="ref"}, [44](#nep13393-bib-0044){ref-type="ref"}, [45](#nep13393-bib-0045){ref-type="ref"}, [46](#nep13393-bib-0046){ref-type="ref"}, [47](#nep13393-bib-0047){ref-type="ref"}, [48](#nep13393-bib-0048){ref-type="ref"}, [49](#nep13393-bib-0049){ref-type="ref"}, [50](#nep13393-bib-0050){ref-type="ref"}, [51](#nep13393-bib-0051){ref-type="ref"} Mutations in the *NPHP1* gene are the most common, being reported in approximately 20% of cases. Each of the remaining *NPHP* genes probably account for 1% or fewer of all cases of NPHP, and around two‐thirds of cases remain genetically unknown.[41](#nep13393-bib-0041){ref-type="ref"}

###### 

Genes mutated in isolated nephronophthisis (NPHP)‐ and NPHP‐associated syndromes

  Gene                     Chromosome   Protein                                                         Location                                             Interaction partners                                                                                                     Functionary mechanism                                                                                                                                                    Disorders associated with mutations                                                                                                                                                   Reference
  ------------------------ ------------ --------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *NPHP1*                  2q12.3       Nephrocystin‐1                                                  Adherens junction, focal adhesion, transition zone   Inversin, nephrocystin‐3, nephrocystin‐4, filamin A and B, tensin, β‐tubulin, PTK2B, p130 Cas, focal adhesion kinase 2   Maintains the cellular scaffolding or cytoskeleton, role in cell--cell adhesion and cell signalling                                                                      NPHP, SLSN, JBTS                                                                                                                                                       [12](#nep13393-bib-0012){ref-type="ref"}
  *NPHP2/INVS*             9q21‐22      Inversin                                                        Inversin compartment                                 Nephrocystin‐1, nephrocystin‐3, calmodulin, catenins, β‐tubulin, APC2                                                    Acts in Wnt pathway and planar cell polarity                                                                                                                             Infantile NPHP, SLSN, *Situs inversus*, congenital heart defects                                                                                                       [13](#nep13393-bib-0013){ref-type="ref"}
  *NPHP3*                  3q22.1       Nephrocystin‐3                                                  Inversin compartment, axoneme                        Nephrocystin‐1, inversin, NEK8, ANKS6, PTK2B, BCAR1                                                                      Inhibits Wnt pathway                                                                                                                                                     NPHP, liver fibrosis, RP, *Situs inversus*, MKS, SLSN, congenital heart defects                                              [14](#nep13393-bib-0014){ref-type="ref"}, [15](#nep13393-bib-0015){ref-type="ref"}, [16](#nep13393-bib-0016){ref-type="ref"}
  *NPHP4*                  1p36.31      Nephrocystin‐4                                                  Transition zone                                      Nephrocystin‐1, BCAR1, PTK2B, p130Cas, filamin, tensin                                                                   Inhibits Wnt and Hippo pathways                                                                                                                                          Juvenile NPHP, RP, OMA, SLSN, liver fibrosis                                                                                                                           [17](#nep13393-bib-0017){ref-type="ref"}
  *NPHP5/IQCB1*            3q13.33      Nephrocystin‐5/IQ motif containing B1                           Transition zone, basal body                          Calmodulin, RPGR, nephrocystin‐1, nehrocystin‐4, nephrocystin‐6                                                          Forms complexes with RPGR                                                                                                                                                Juvenile NPHP, early‐onset RP, LCA                                                                                                                                     [18](#nep13393-bib-0018){ref-type="ref"}
  *NPHP6/CEP290*           12q21.32     Nephrocystin‐6/centrosomal protein 290                          Transition zone, centrosome                          ATF4, nephrocystin‐5, CC2D2A, TMEM67                                                                                     Regulates activity of transcription factor ATF4/CREB2, role in cAMP‐dependent renal cyst formation, cell signalling, DNA damage response (DDR), and renal cystogenesis   NPHP, RP, LCA, JBTS, MKS                                                           [19](#nep13393-bib-0019){ref-type="ref"}, [20](#nep13393-bib-0020){ref-type="ref"}, [21](#nep13393-bib-0021){ref-type="ref"}, [22](#nep13393-bib-0022){ref-type="ref"}, [23](#nep13393-bib-0023){ref-type="ref"}
  *NPHP7/GLIS2*            16p13.3      Nephrocystin‐7/ GLI similar 2                                   Nucleus                                              N/A                                                                                                                      Regulates Hedgehog signalling                                                                                                                                            NPHP                                                                                                                                              [24](#nep13393-bib-0024){ref-type="ref"}, [25](#nep13393-bib-0025){ref-type="ref"}
  *NPHP8/RPGRIP1L/MKS5*    16q12.2      Nephrocystin‐8/ RPGRIP1‐like                                    Transition zone                                      Nephrocystin‐1, nephrocystin‐4                                                                                           Involved in Shh signalling                                                                                                                                               Juvenile NPHP, JBTS, MKS, RP, LCA, COACH                                                                                                                               [26](#nep13393-bib-0026){ref-type="ref"}
  *NPHP9/NEK8*             17q11.2      Nephrocystin‐9/ NIMA‐related kinase 8                           Inversin compartment                                 ANKS6                                                                                                                    Regulates cell cycle, involved in Hippo and DDR signalling                                                                                                               Infantile NPHP                                                                                                                                    [27](#nep13393-bib-0027){ref-type="ref"}, [28](#nep13393-bib-0028){ref-type="ref"}
  *NPHP10/SDCCAG8/SLSN7*   1q43‐q44     Nephrocystin‐10/ Serologically defined colon cancer antigen 8   Basal body                                           Nephrocystin‐5, OFD1                                                                                                     Involved in DDR signalling                                                                                                                                               Juvenile NPHP, RP, SLSN, BBS                                                                                                                      [29](#nep13393-bib-0029){ref-type="ref"}, [30](#nep13393-bib-0030){ref-type="ref"}
  *NPHP11/ TMEM67/MKS3*    8q22.1       Nephrocystin‐11/ Transmembrane protein 67                       Transition zone                                      Nephrocystin‐1, nephrocystin‐4, nephrocystin‐6, CEP290, MKS1, TMEM216, nesprin‐2                                         Maintains cellular structure and mitigates centrosome migration                                                                                                          NPHP, JBTS, MKS, liver fibrosis, COACH                                                                                                            [31](#nep13393-bib-0031){ref-type="ref"}, [32](#nep13393-bib-0032){ref-type="ref"}
  *NPHP12/TTC21B/JBTS11*   2q24.3       Nephrocystin‐12/ Intraflagellar transport protein 139           IFT‐A                                                Ciliopathy modifier                                                                                                      Regulates retrograde trafficking in the primary cilium, regulates Hedgehog signalling                                                                                    Juvenile NPHP, JS, MKS, JBTS                                                                                                                                           [33](#nep13393-bib-0033){ref-type="ref"}
  *NPHP13/WDR19*           4p14         Nephrocystin‐13/ WD repeat domain 19/IFT protein 144            IFT‐A                                                N/A                                                                                                                      Participates in retrograde IFT; acts in ciliogenesis                                                                                                                     NPHP, JS, RP, Caroli, Sensenbrenner syndrome                                                                                                      [34](#nep13393-bib-0034){ref-type="ref"}, [35](#nep13393-bib-0035){ref-type="ref"}
  *NPHP14 /ZNF423*         16q12.1      Nephrocystin‐14/ Zinc finger protein 423                        Nucleus                                              DDR protein PARP1, nephrocystin‐6                                                                                        Involved in DDR signalling                                                                                                                                               Infantile NPHP, JBTS, S*itus inversus*                                                                                                                                 [36](#nep13393-bib-0036){ref-type="ref"}
  *NPHP15/ CEP164*         11q23.3      Nephrocystin‐15 centrosomal protein 164                         Basal body                                           Nephrocystin‐3, nephrocystin‐4, TTBK2, ATRIP, CCDC92, CEP83, Dvl3                                                        Involved in DDR signalling, regulates ciliogenesis                                                                                                                       NPHP, liver fibrosis, RP, JBTS                                                                                                                                         [37](#nep13393-bib-0037){ref-type="ref"}
  *NPHP16/ANKS6*           9q22.33      Nephrocystin‐16/ANKS6                                           Axoneme, inversin compartment                        INVS, nephrocystin‐3, NEK8, ANKS3, NEK7, BICC1, HIF1AN                                                                   Connects key components of NEK8, INVS, and NPHP3                                                                                                                         NPHP, liver fibrosis, S*itus inversus*                                                                                       [38](#nep13393-bib-0038){ref-type="ref"}, [39](#nep13393-bib-0039){ref-type="ref"}, [40](#nep13393-bib-0040){ref-type="ref"}
  *NPHP17/IFT172*          2p23.3       Nephrocystin‐17/ IFT protein 172                                IFT‐B                                                IFT80, IFT140                                                                                                            Involved in intraflagellar transport                                                                                                                                     NPHP, JS, JBTS, MZSDS                                                                                                                                                  [41](#nep13393-bib-0041){ref-type="ref"}
  *NPHP18 /CEP83*          12q22        Nephrocystin‐18/centrosomal protein 83                          Basal body                                           IFT20, CEP164                                                                                                            N/A                                                                                                                                                                      NPHP, liver fibrosis, mental retardation, hydrocephalus                                                                                                                [42](#nep13393-bib-0042){ref-type="ref"}
  *NPHP19/DCDC2*           6p22.3       Doublecortin domain‐containing protein 2                        Axoneme                                              DVL                                                                                                                      Involved in Wnt signalling                                                                                                                                               NPHP, renal‐hepatic ciliopathy                                                                                                                                         [43](#nep13393-bib-0043){ref-type="ref"}
  *NPHP20/MAPKBP1*         15q15.1      Mitogen‐activated protein kinase binding protein 1              Cytoplasm                                            N/A                                                                                                                      Involved in DDR signalling and JNK signalling                                                                                                                            NPHP                                                                                                                                                                   [2](#nep13393-bib-0002){ref-type="ref"}
  *NPHP1L /XPNPEP3*        22q13        X‐prolyl aminopeptidase 3                                       Mitochondria                                         Cleaves LRRC50, ALMS1, nephrocystin‐6                                                                                    Interferes with cilia function by cleaving certain cilial proteins                                                                                                       NPHP, myocardiosis, epilepsy                                                                                                                      [44](#nep13393-bib-0044){ref-type="ref"}, [45](#nep13393-bib-0045){ref-type="ref"}
  *NPHP2L /SLC41A1*        1q32.1       Solute carrier family 41 member 1                               Tubules at the borders of the cortex and medulla     N/A                                                                                                                      Affects Mg^2+^ transport                                                                                                                                                 NPHP, bronchiectasia                                                                                                                                                   [46](#nep13393-bib-0046){ref-type="ref"}
  *TRAF3IP1*               2q37.3       TRAF3 interacting protein 1                                     Axonemes, basal bodies                               N/A                                                                                                                      Affects microtubule stabilization by IFT54                                                                                                                               NPHP, SLSN, RP                                                                                                                                                         [47](#nep13393-bib-0047){ref-type="ref"}
  *AH11/JBTS3*             6q23.3       Jouberin                                                        Basal bodies                                         N/A                                                                                                                      Affects cerebellar and cortical development                                                                                                                              JBTS, RP                                                                                                                                          [48](#nep13393-bib-0048){ref-type="ref"}, [49](#nep13393-bib-0049){ref-type="ref"}
  *CC2D2A/MKS6*            4p15.32      Coiled coil and C2 domain containing 2A                         Basal bodies                                         CEP290                                                                                                                   Acts in ciliogenesis                                                                                                                                                     MKS, COACH, JBST                                                                                                                                  [50](#nep13393-bib-0050){ref-type="ref"}, [51](#nep13393-bib-0051){ref-type="ref"}

ALMS1, Alstrom Syndrome 1; APC2, anaphase‐promoting complex 2; ATF4, activating transcription factor 4; ATRIP, ATR interacting protein; BBS, Bardet‐Biedl syndrome; BCAR1, breast cancer anti‐estrogen resistance 1; BICC1, Bicaudal‐C1; CAD, cranioectodermal dysplasia; CCDC92, coiled‐coil domain containing 92; CC2D2A, coiled‐coil and C2 domain containing 2A; CEP290, centrosomal protein 290; CHD, congenital heart disease; COACH, cerebellar vermis hypo/aplasia, oligophrenia, congenital ataxia, ocular coloboma and hepatic fibrosis; DVL3, dishevelled 3; HIF1AN, hypoxia inducible factor 1 alpha subunit inhibitor; IFT, intraflagellar transport; JATD, Jeune asphyxiating thoracic dysplasia; JBTS, Joubert syndrome; JS, Jeune syndrome; LCA, Leber congenital amaurosis; LRRC50, leucine‐rich repeat containing protein 50; MKS, Meckel‐Gruber syndrome; MZSDS, Mainzer‐Saldino syndrome; OFD1, oral‐facial‐digital protein1; OMA, oculomotor apraxia; PTK2B, protein tyrosine kinase 2B; RP, retinitis pigmentosa; RPGR, retinitis pigmentosa GTPase regulator; SBS, Sensenbrenner syndrome; SLSN, Senior‐Loken syndrome; TMEM67,transmembrane protein 67; TTBK2, Tau‐tubulin kinase 2.

Most nephrocystins are located in the transition zone, inversin compartment, or subunits of intraflagellar transport (IFT) complexes.[6](#nep13393-bib-0006){ref-type="ref"} However, genome‐wide homozygosity mapping identified pathogenic mutations in *NPHP1L* and *NPHP2L* of which the protein product localizes to mitochondria.[52](#nep13393-bib-0052){ref-type="ref"} Currently, at least four distinct nephrocystin modules have been found: the NPHP1‐4‐8 module, NPHP2‐3‐9‐ANKS6 module, NPHP5‐6 module, and MKS module (Fig. [1](#nep13393-fig-0001){ref-type="fig"}). These nephrocystin modules are related to different signalling pathways, including the Wnt pathway, Hedgehog pathway, DNA damage response (DDR) pathway, Hippo pathway, intracellular calcium signalling pathway, cAMP signalling pathway, and mTOR pathway.

![Subcellular localization of different nephrocystin module.](NEP-23-904-g001){#nep13393-fig-0001}

NPHP shows genetic and phenotypic heterogeneity. Mutations in single ciliary genes are often associated with multiple phenotypes (Table [1](#nep13393-tbl-0001){ref-type="table"} and Table [3](#nep13393-tbl-0003){ref-type="table"}). Single locus allelism is insufficient to explain the variability in phenotypic heterogeneity in NPHP. Digenic and triallelic inheritance may provide an explanation. Triallelic inheritance was first demonstrated for BBS.[53](#nep13393-bib-0053){ref-type="ref"}To date, oligogenic inheritance has been noted in some patients with mutations in *NPHP1*, *NPHP5*, *NPHP6*, *NPHP8*, *NPHP9*, *NPHP11*, and *TTC21B* genes.[12](#nep13393-bib-0012){ref-type="ref"}, [54](#nep13393-bib-0054){ref-type="ref"}, [55](#nep13393-bib-0055){ref-type="ref"}, [56](#nep13393-bib-0056){ref-type="ref"}

APPROACH TO CLINICAL DIAGNOSIS OF NPHP {#nep13393-sec-0004}
======================================

The diagnosis of NPHP is suggested by clinical features and confirmed by a positive genetic test (Fig. [2](#nep13393-fig-0002){ref-type="fig"}). The role of renal biopsy in diagnosis is controversial. Renal biopsy should be limited to cases in which tissue diagnosis can be used to distinguish it from other differential diagnoses. Molecular genetic analysis is currently the only method available to diagnose NPHP and thus provide patients and families with an unequivocal diagnosis. Due to an increasing number of potentially causative monogenic genes and to advances in next‐generation sequencing, whole‐exome sequencing has mostly replaced targeted‐sequencing panels in the diagnosis of NPHP.[57](#nep13393-bib-0057){ref-type="ref"} Using this method, a causative single‐gene mutation can be detected in up to 60% of cases depending on the composition of the cohort. However, the absence of mutation is not sufficient to exclude the diagnosis of NPHP. Most importantly, genetic testing should always be combined with thorough phenotyping and genetic counseling.

![Approach to clinical diagnosis of nephronophthisis (NPHP).](NEP-23-904-g002){#nep13393-fig-0002}

Early onset autosomal dominant polycystic kidney disease and autosomal recessive polycystic kidney disease are often in the main differential diagnosis for patients with NPHP. Renal imaging may be useful in differential diagnosis. But genetic testing is required to make a definite diagnosis.

TREATMENT OF NPHP {#nep13393-sec-0005}
=================

There is no specific therapy for NPHP. Management is supportive, focusing on slowing the progression of CKD, controlling complications, and maintaining the promotion of growth. This disease does not recur after transplantation, so renal transplantation is the preferred renal replacement therapy.

Some potential therapeutic interventions have arisen from several lines of investigation into the pathogenesis of NPHP. Various personalized drugs include isosorbide dinitrate and tolvaptan (vasopressin V2 receptor antagonist),[58](#nep13393-bib-0058){ref-type="ref"} dimethyl fumarate,[59](#nep13393-bib-0059){ref-type="ref"} rapamycin (mTOR inhibitor),[60](#nep13393-bib-0060){ref-type="ref"} roscovitine and its analog S‐CR8 (cyclin‐dependent kinases inhibitor),[61](#nep13393-bib-0061){ref-type="ref"} purmorphamine (Shh signalling pathway agonist),[62](#nep13393-bib-0062){ref-type="ref"} paclitaxel,[63](#nep13393-bib-0063){ref-type="ref"} regulation of transcription factor Glis2/NPHP7 by SUMOylation,[64](#nep13393-bib-0064){ref-type="ref"} and FR167653 (p38 MAPK pathway inhibitor).[65](#nep13393-bib-0065){ref-type="ref"} Despite the many promising interventions that have arisen from preclinical studies, no clinical trials have yet been conducted in NPHP patients. Furthermore, large numbers of compounds which may be potential therapies are being screened in the zebrafish models of NPHP.[66](#nep13393-bib-0066){ref-type="ref"}

The lack of a clear‐cut genotype--phenotype correlation remains a major challenge for physicians treating children with NPHP, even though the development of a single comprehensive histopathology and the discovery of specific disease genes and molecular mechanisms have significantly improved our understanding of NPHP. Only about 30% of NPHP patients have clear genetic mutations, suggesting that more NPHP genes have yet to be discovered. Novel genes will enable us to better understand the pathogenesis and relationship between cilia and cystic diseases. It is necessary to find new therapeutic strategies and develop alternative treatments other than conservative approaches and renal replacement therapy.
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